Fluconazole Dosing Guidelines

Age-Based Dosing Transition

• The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines recommend that patients aged 15 years and older should receive standard adult doses of fluconazole, rather than pediatric weight-based dosing 1, 2, 3, 4, 5
• At age 15, patients should receive standard adult doses rather than pediatric weight-based dosing, as stated by the ESCMID guidelines 1, 3, 4
• For patients aged 12-14 years weighing >50 kg, adult dosing is also appropriate, but at exactly 15 years, adult dosing applies regardless of weight 1, 3

Specific Dosing by Indication

For Invasive Candidiasis/Candidemia

• A loading dose of 800 mg (12 mg/kg) on day 1, then 400 mg (6 mg/kg) daily is recommended for invasive candidiasis, as per the Infectious Diseases Society of America (IDSA) guidelines 6, 7
• Treatment should continue for 2 weeks after documented clearance from bloodstream and resolution of symptoms 6
• Both oral and intravenous administration are bioequivalent, with >93% oral bioavailability 2, 5

For Oropharyngeal Candidiasis

• Moderate to severe disease should be treated with 100-200 mg daily for 7-14 days, as recommended by the IDSA guidelines 7
• For mild disease, topical agents may be preferred initially 7

For Esophageal Candidiasis

• Treatment with 200-400 mg (3-6 mg/kg) daily for 14-21 days is recommended, as per the IDSA guidelines 7
• Intravenous administration at 400 mg (6 mg/kg) daily is an alternative if oral therapy cannot be tolerated 7

For Prophylaxis in High-Risk Settings

• The ESCMID guidelines recommend 8-12 mg/kg daily (maximum 400 mg) for patients undergoing allogeneic HSCT or with acute leukemia 1, 2, 3, 5
• Duration varies by clinical context: day 0 to day +75 post-transplant for HSCT, or after chemotherapy until neutrophil recovery for leukemia 1, 2

Important Clinical Considerations

Common Pitfalls to Avoid

• The ESCMID guidelines advise against using pediatric weight-based dosing (8-12 mg/kg) without a maximum cap at age 15, as this would result in adult doses anyway 1, 2
• The IDSA guidelines recommend avoiding fluconazole in patients with recent azole exposure when treating suspected invasive candidiasis, as resistance is more likely 6, 8
• The ESCMID guidelines advise against using fluconazole for empiric therapy if institutional rates of fluconazole-resistant Candida species (C. glabrata, C. krusei) are high 1, 2